United States Heparin Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 1.33 Billion |
| Market Size (2029) | USD 1.82 Billion |
| CAGR (2024 - 2029) | 6.54 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
United States Heparin Market Analysis
The United States Heparin Market size is estimated at USD 1.33 billion in 2024, and is expected to reach USD 1.82 billion by 2029, growing at a CAGR of 6.54% during the forecast period (2024-2029).
The COVID-19 pandemic has significantly impacted the United States heparin market. According to an article titled, 'Response of US hospitals to elective surgical cases in the COVID-19 pandemic' published in October 2020, an early rapid decrease in United States surgical case volumes beginning mid-March 2020 was observed by the researchers. It found out that during the week of April, it was observed that there was a 71% reduction compared with the same week in 2019. Thus, the COVID-19 pandemic has affected surgical procedures tremendously which might impact the demand for heparin. Additionally, in September 2020, as a part of its 'Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)' initiative, the National Institutes of Health launched two of three adaptive Phase 3 clinical trials that will evaluate the safety and effectiveness of blood thinners (including heparin) to treat adults diagnosed with COVID-19. Positive results might prove advantages for COVID-19 patients who suffer from life-threatening blood clots.
The market is primarily driven by the rising geriatric population and an increase in incidences of chronic diseases like cardiovascular diseases and cancers. The United States has a huge burden of cancer cases. The high burden of cancer can be explained by the latest statistics provided by the International Agency for Research on Cancer, which states that in 2020, there was an estimated 2 281 658 new cancer cases diagnosed and 612 390 cancer deaths in the United States. Heparin can affect the angiogenesis, proliferation, migration and invasion of cancer cells via multiple mechanisms. The high cancer burden is expected to boost market growth.
The major market players are focusing on research and development activities to bring new and reliable treatments in the market, and they are also focusing on the product launches to effectively treat chronic diseases in the country. For instance, in March 2021, researchers from the Rhode Island Hospital started a study that determineshow quicklyheparin induced anticoagulation occurs when two different point of care activated clotting technologies (iSTATand Hemochron)are used in patients.This is an important study since promptness of heparin anticoagulation is essentialduring moststructural heart procedures.rdiology's 70th Annual Scientific Session (ACC.21).
However, side-effects of heparin are refraining the patients from its use that is hindering the market growth.
United States Heparin Market Trends
This section covers the major market trends shaping the US Heparin Market according to our research experts:
Deep Vein Thrombosis (DVT) is expected to dominate the market
By application, deep-vein thrombosis is expected to witness significant growth. A deep-vein thrombosis (DVT) is defined as a blood clot that forms within the deep veins that might occur in the veins of the arms and the mesenteric and cerebral veins. As of 2020, according to the Centers for Disease Control and Prevention (CDC), the exact number of people infected with deep vein thrombosis was unknown, although about 900,000 people were expected to be affected each year in the United States. According to the CDC, one-third of about 33% of people with deep vein thrombosis will have a recurrence within ten years. The Centers for Disease Control and Prevention (CDC) also estimated that 60,000-100,000 Americans die of deep vein thrombosis each year while 10 to 30% of people can die within one month of diagnosis.
Thus, the increasing prevalence of deep vein thrombosis is expected to fuel the production of demand for heparin-based products, thereby augmenting the market growth over the forecast period.
United States Heparin Industry Overview
The United States Heparin market is a consolidated market, owing to the presence of a few major players in the market. The major market players, such as Baxter International Inc., Pfizer Inc., Sagent Pharmaceuticals, Mylan N.V., Bayer AG hold a significant market share in the country.
United States Heparin Market Leaders
-
Pfizer Inc.
-
B Braun Melsungen AG
-
Baxter International Inc.
-
Sagent Pharmaceuticals
-
Mylan N.V.
*Disclaimer: Major Players sorted in no particular order
United States Heparin Market News
- In June 2021, Bayers development partner, Janssen Research & Development, LLC has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (USFDA) for the use of the oral anticoagulant Xarelto (rivaroxaban) in pediatric patients for the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years of age after at least 5 days of initial parenteral anticoagulant treatment.
- In April 2021, B. Braun Medical Inc. launched its Heparin Sodium Injection, USP - the first Heparin 5,000 USP Unit / 0.5 mL prefilled syringe with attached safety needle for subcutaneous and intravenous use in the United States.
United States Heparin Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Prevalence of Chronic Diseases
- 4.2.2 Rise in Geriatric Population
-
4.3 Market Restraints
- 4.3.1 Side Effects of Heparin
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value-USD Million)
-
5.1 By Product
- 5.1.1 Unfractionated Heparin
- 5.1.2 Low Molecular Weight Heparin (LMWH)
- 5.1.3 Ultra-Low Molecular Weight Heparin (ULMWH)
-
5.2 By Source
- 5.2.1 Bovine
- 5.2.2 Porcine
-
5.3 By Application
- 5.3.1 Atrial Fibrillation and Heart Attack
- 5.3.2 Stroke
- 5.3.3 Deep Vein Thrombosis (DVT)
- 5.3.4 Others
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Baxter International Inc.
- 6.1.2 Pfizer Inc.
- 6.1.3 Sagent Pharmaceuticals
- 6.1.4 Mylan N.V.
- 6.1.5 Bayer AG
- 6.1.6 B. Braun Melsungen AG
- 6.1.7 Scientific Protein Laboratories LLC
- 6.1.8 Sanofi S.A
- 6.1.9 Merck & Co. Inc
- 6.1.10 Meitheal Pharmaceuticals
- 6.1.11 Leo Pharma A/S
- 6.1.12 Nanjing King-Friend Biochemical Pharmaceutical
- 6.1.13 Amphastar Pharmaceuticals
- 6.1.14 Shenzhen Hepalink
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
United States Heparin Industry Segmentation
As per the scope of the report, heparin is used as an anticoagulation agent which allows the body's natural clot lysis mechanisms to work normally to break down clots that have formed. The United States heparin market is segmented by Product(Unfractionated Heparin, Low Molecular Weight Heparin(LMWH) and Ultra-Low Molecular Weight Heparin(ULMWH)), Source (Bovine, Porcine), and Application (Atrial Fibrillation and Heart Attack, Stroke, Deep Vein Thrombosis (DVT) and Others). The report offers the value (in USD million) for the above segments.
| By Product | Unfractionated Heparin |
| Low Molecular Weight Heparin (LMWH) | |
| Ultra-Low Molecular Weight Heparin (ULMWH) | |
| By Source | Bovine |
| Porcine | |
| By Application | Atrial Fibrillation and Heart Attack |
| Stroke | |
| Deep Vein Thrombosis (DVT) | |
| Others |
United States Heparin Market Research FAQs
How big is the United States Heparin Market?
The United States Heparin Market size is expected to reach USD 1.33 billion in 2024 and grow at a CAGR of 6.54% to reach USD 1.82 billion by 2029.
What is the current United States Heparin Market size?
In 2024, the United States Heparin Market size is expected to reach USD 1.33 billion.
Who are the key players in United States Heparin Market?
Pfizer Inc., B Braun Melsungen AG, Baxter International Inc., Sagent Pharmaceuticals and Mylan N.V. are the major companies operating in the United States Heparin Market.
What years does this United States Heparin Market cover, and what was the market size in 2023?
In 2023, the United States Heparin Market size was estimated at USD 1.25 billion. The report covers the United States Heparin Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the United States Heparin Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
United States Heparin Industry Report
Statistics for the 2024 United States Heparin market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. United States Heparin analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
